Nonproliferative epithelial alteration and expression of estrogen receptor and Ki67 in the contralateral breast of women treated with tamoxifen for breast cancer

Sales, José Fernando de Souza; Cabello, César; Alvarenga, Marcelo; Torresan, Renato Zocchio; Duarte, Giuliano Mendes

doi:10.1016/j.breast.2006.10.005

Cited by 2 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tamoxifen and other estrogen receptor modulators, such as raloxifene, have also been shown to decrease breast density particularly in pre-menopausal woman [17–21]. The underlying mechanism is not well known yet, but reducing the proliferative activity of breast tissues seems to be one major reason [22–24]. …”

Section: Introductionmentioning

confidence: 99%

Reduction of breast density following tamoxifen treatment evaluated by 3-D MRI: preliminary study

Chen

Chang

et al. 2011

Magnetic Resonance Imaging

View full text Add to dashboard Cite

This study analyzed the change of breast density in women receiving tamoxifen treatment using 3-D MRI. Sixteen women were studied. Each woman received breast MRI before and after tamoxifen. The breast and the fibroglandular tissue were segmented using a computer-assisted algorithm, based on T1-weighted images. The fibroglandular tissue volume (FV) and breast volume (BV) were measured and the ratio was calculated as the percent breast density (%BD). The changes in breast volume (ΔBV), fibroglandular tissue volume (ΔFV), and percent density (Δ %BD) between two MRI studies were analyzed and correlated with treatment duration and baseline breast density. The ΔFV showed a reduction in all 16 women. The Δ%BD showed a mean reduction of 5.8%. The reduction of FV was significantly correlated with baseline FV (P<0.001) and treatment duration (P=0.03). The percentage change in FV was correlated with duration (P=0.049). The reduction in %BD was positively correlated with baseline %BD (p=0.02). Women with higher baseline %BD showed more reduction of %BD. 3D MRI may be useful for the measurement of the small changes of ΔFV and Δ%BD after tamoxifen. These changes can potentially be used to correlate with the future reduction of cancer risk.

show abstract

Section: Introductionmentioning

confidence: 99%

Reduction of breast density following tamoxifen treatment evaluated by 3-D MRI: preliminary study

Chen

Chang

et al. 2011

Magnetic Resonance Imaging

View full text Add to dashboard Cite

show abstract

The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology

et al. 2008

View full text Add to dashboard Cite

The ability of mifepristone to block breast epithelial cell proliferation in premenopausal women may prove beneficial when used for contraceptive purposes or for other gynaecological indications. Future studies should address a possible antiproliferative effect in the post-menopausal breast tissue during hormone replacement therapy. Our results implicate a possible protective effect of mifepristone on the breast epithelium. ClinicalTrials.gov NCT00579475.

show abstract

Nonproliferative epithelial alteration and expression of estrogen receptor and Ki67 in the contralateral breast of women treated with tamoxifen for breast cancer

Cited by 2 publications

References 23 publications

Reduction of breast density following tamoxifen treatment evaluated by 3-D MRI: preliminary study

Reduction of breast density following tamoxifen treatment evaluated by 3-D MRI: preliminary study

The effect of mifepristone on breast cell proliferation in premenopausal women evaluated through fine needle aspiration cytology

Contact Info

Product

Resources

About